Evidence map›Paper›PMID 40376725›Full record

ArticlePathology international2025

Proposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types.

Ryoko Rikitake, Yasushi Yatabe, Yoko Yamamoto, Tatsunori Shimoi, Shintaro Iwata, Yasushi Goto, Yu Mizushima, Akira Kawai, Takahiro Higashi

Abstract read
In one paragraph

Article in Pathology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryoko RikitakeDivision of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0232-8283
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1788-559X
Yoko YamamotoDivision of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Tatsunori ShimoiRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Shintaro IwataRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yu MizushimaDivision of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Akira KawaiRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Takahiro HigashiDivision of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9933-2106

Funding

This project was funded by the Ministry of Health, Labour, and Welfare Grants-in-Aid for Scientific Research (project name: "Research on developing a network providing cancer information and consultation support for rare cancers." Grant number: 23EA1013).
6 · The paper itself

Abstract

Several classifications have been proposed to define rare cancers; however, the pathophysiological understanding of tumors evolves rapidly. We propose a New Classification of Rare Cancer (NCRC) using the updated International Classification of Diseases for Oncology 3.2 coding system and World Health Organization Classification of Tumors 5th edition. We applied patient data recorded in the National Cancer Registry of Japan to the new classification, setting a cut-off of a crude incidence rate of 6 cases/100 000/year to define rare cancers, and developed a list of rare cancers in Japan from 2016 to 2019. The NCRC system identified various rare cancers, comprising 20.0% of all cancer diagnoses in this period. To examine this classification system's performance, we compared rare/non-rare labeling of cancers by the Surveillance of Rare Cancers in Europe (RARECARENet) project and NCRC system. Compared with cases using the RARECARENet classification in Europe, 69 351 cases/year (6.8%) switched status with our classification, with 45 293 and 232 109 cases (4 years) switching from rare and non-rare, respectively. Major differences included diffuse large B-cell lymphomas, some thyroid cancers, oral cavity and lip cancers, and squamous cell carcinoma of the uterine cervix. As the NCRC includes newly classified tumor entities, it warrants validation using other diverse cohorts.

Indexed as

NeoplasmsRare DiseasesEuropeFemaleHumansIncidenceInternational Classification of DiseasesJapanMaleRegistriescancer classificationInternational Classification of DiseasesNational Cancer Registryrare cancerSurveillance of Rare Cancers in Europe (RARECARE)

Identifiers

PMID40376725
PMCPMC12184288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.